Precigen, Inc. (PGEN)
8.54
+0.33
(+4.02%)
USD |
NASDAQ |
Oct 02, 16:00
8.52
-0.02
(-0.23%)
After-Hours: 20:00
Precigen Enterprise Value : 3.118B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 3.118B |
| October 01, 2026 | 2.999B |
| September 30, 2026 | 3.125B |
| September 29, 2026 | 2.942B |
| September 28, 2026 | 2.856B |
| September 25, 2026 | 2.835B |
| September 24, 2026 | 2.817B |
| September 23, 2026 | 2.724B |
| September 22, 2026 | 2.885B |
| September 21, 2026 | 2.817B |
| September 18, 2026 | 2.845B |
| September 17, 2026 | 2.878B |
| September 16, 2026 | 2.722B |
| September 15, 2026 | 2.566B |
| September 14, 2026 | 2.512B |
| September 11, 2026 | 2.512B |
| September 10, 2026 | 2.452B |
| September 09, 2026 | 2.495B |
| September 08, 2026 | 2.520B |
| September 04, 2026 | 2.602B |
| September 03, 2026 | 2.616B |
| September 02, 2026 | 2.570B |
| September 01, 2026 | 2.516B |
| August 31, 2026 | 2.541B |
| August 28, 2026 | 2.548B |
| Date | Value |
|---|---|
| August 27, 2026 | 2.634B |
| August 26, 2026 | 2.717B |
| August 25, 2026 | 2.666B |
| August 24, 2026 | 2.627B |
| August 21, 2026 | 2.638B |
| August 20, 2026 | 2.724B |
| August 19, 2026 | 2.623B |
| August 18, 2026 | 2.477B |
| August 17, 2026 | 2.405B |
| August 14, 2026 | 2.244B |
| August 13, 2026 | 2.384B |
| August 12, 2026 | 2.512B |
| August 11, 2026 | 2.516B |
| August 10, 2026 | 2.566B |
| August 07, 2026 | 2.649B |
| August 06, 2026 | 2.534B |
| August 05, 2026 | 2.527B |
| August 04, 2026 | 2.398B |
| August 03, 2026 | 2.427B |
| July 31, 2026 | 2.305B |
| July 30, 2026 | 2.187B |
| July 29, 2026 | 2.011B |
| July 28, 2026 | 2.040B |
| July 27, 2026 | 2.001B |
| July 24, 2026 | 1.993B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Repligen Corp. | 10.13B |
| AC Immune SA | 159.91M |
| Amgen, Inc. | 261.20B |
| Geron Corp. | 720.00M |
| Neurocrine Biosciences, Inc. | 14.56B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 20.07M |
| Revenue (Quarterly) | 54.98M |
| Total Expenses (Quarterly) | 34.91M |
| EPS Diluted (Quarterly) | 0.0485 |
| Gross Profit Margin (Quarterly) | 94.32% |
| Profit Margin (Quarterly) | 36.51% |
| Earnings Yield | -12.87% |
| Normalized Earnings Yield | -9.898 |